RSAR: Post-marketing RX Drug Abuse Surveill Data Denver Health Data Source

The contract supports the continuation of active surveillance for adverse drug events and prescription and over-the-counter drug abuse through data collected from individuals entering or assessed for substance abuse treatment, primarily leveraging Denver Health as the data source. This effort enables the Food and Drug Administration to monitor post-marketing drug abuse trends and inform regulatory decisions and public health initiatives aimed at prevention and intervention. Funding is allocated under both PDUFA and GDUFA to cover all CDER-regulated medical products, with increased resources proposed to enhance data granularity and enable more detailed stratified analysis. The contract isForecasted for October 2026 with a projected posting date of May 25, 2026, and falls under the NAICS code 541990 for other scientific and technical consulting services. The point of contact for program inquiries is the CDER Acquisition Liaison, while the contracting officer role remains to be determined. All activities are focused on maintaining uninterrupted surveillance capabilities critical to public health safety.